GNGBF Quote, Financials, Valuation and Earnings

BioArctic AB has a net margin of 8.53% compared to Getinge AB's net margin of -4.8%. Getinge AB's return on equity of 7.64% beat BioArctic AB's return on equity of 52.54%.

Getinge AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Getinge AB has higher upside potential than BioArctic AB, analysts believe Getinge AB is more attractive than BioArctic AB.

Getinge AB has a beta of 0.726, which suggesting that the stock is 27.376% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Getinge AB has a quarterly dividend of $0.47 per share corresponding to a yield of 2.04%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Getinge AB pays 57.3% of its earnings as a dividend. BioArctic AB pays out 17.32% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Getinge AB quarterly revenues are $1.1B, which are larger than BioArctic AB quarterly revenues of $19.6M. Getinge AB's net income of $92.4M is higher than BioArctic AB's net income of -$938.5K. Notably, Getinge AB's price-to-earnings ratio is 27.03x while BioArctic AB's PE ratio is 30.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Getinge AB is 1.77x versus 14.99x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of 8.53% compared to Getinge AB's net margin of 21.72%. Getinge AB's return on equity of 7.64% beat Camurus AB's return on equity of 19.19%.

Getinge AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Getinge AB has higher upside potential than Camurus AB, analysts believe Getinge AB is more attractive than Camurus AB.

Getinge AB has a beta of 0.726, which suggesting that the stock is 27.376% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.17%.

Getinge AB has a quarterly dividend of $0.47 per share corresponding to a yield of 2.04%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Getinge AB pays 57.3% of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend. Getinge AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Getinge AB quarterly revenues are $1.1B, which are larger than Camurus AB quarterly revenues of $49.4M. Getinge AB's net income of $92.4M is higher than Camurus AB's net income of $10.7M. Notably, Getinge AB's price-to-earnings ratio is 27.03x while Camurus AB's PE ratio is 44.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Getinge AB is 1.77x versus 14.30x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of 8.53% compared to Getinge AB's net margin of -217.19%. Getinge AB's return on equity of 7.64% beat Hansa Biopharma AB's return on equity of --.

Getinge AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Getinge AB has higher upside potential than Hansa Biopharma AB, analysts believe Getinge AB is more attractive than Hansa Biopharma AB.

Getinge AB has a beta of 0.726, which suggesting that the stock is 27.376% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.963%.

Getinge AB has a quarterly dividend of $0.47 per share corresponding to a yield of 2.04%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Getinge AB pays 57.3% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend. Getinge AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Getinge AB quarterly revenues are $1.1B, which are larger than Hansa Biopharma AB quarterly revenues of $8.1M. Getinge AB's net income of $92.4M is higher than Hansa Biopharma AB's net income of -$17.5M. Notably, Getinge AB's price-to-earnings ratio is 27.03x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Getinge AB is 1.77x versus 10.42x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.